Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. 2019 replace of the American Faculty of Rheumatology/Spondylitis Affiliation of America/Spondyloarthritis Analysis and Remedy Community Suggestions for the remedy of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–613.
van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr, Group AS. Efficacy and security of adalimumab in sufferers with ankylosing spondylitis: outcomes of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46.
Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84.
Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and security of golimumab in sufferers with ankylosing spondylitis: outcomes of a randomized, double-blind, placebo-controlled, section III trial. Arthritis Rheum. 2008;58(11):3402–12.
Manabe H, Nasu Y, Komiyama T, Furumatsu T, Kitamura A, Miyazawa S, Ninomiya Y, Ozaki T, Asahara H, Nishida Okay. Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial progress issue by rheumatoid synovial fibroblasts. Inflamm Res. 2008;57(1):4–10.
Schett G, Lories RJ, D’Agostino MA, Elewaut D, Kirkham B, Soriano ER, McGonagle D. Enthesitis: from pathophysiology to remedy. Nat Rev Rheumatol. 2017;13(12):731–41.
Shankar J, Thippegowda PB, Kanum SA. Inhibition of HIF-1alpha exercise by BP-1 ameliorates adjuvant induced arthritis in rats. Biochem Biophys Res Commun. 2009;387(2):223–8.
Braun J, Brandt J, Itemizing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J. Remedy of lively ankylosing spondylitis with infliximab: a randomised managed multicentre trial. Lancet. 2002;359(9313):1187–93.
Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS. HIF-1alpha is important for myeloid cell-mediated irritation. Cell. 2003;112(5):645–57.
Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W. Enbrel Ankylosing Spondylitis Examine, recombinant human tumor necrosis issue receptor (etanercept) for treating ankylosing spondylitis: a randomized, managed trial. Arthritis Rheum. 2003;48(11):3230–6.
Baraliakos X, Heldmann F, Callhoff J, Itemizing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewe R, Leirisalo-Repo M, Sieper J, De Vlam Okay, Pappas D, Kiltz U, Van Der Heijde D, Braun J. Which spinal lesions are related to new bone formation in sufferers with ankylosing spondylitis handled with anti-TNF brokers? An extended-term observational research utilizing MRI and traditional radiography. Ann Rheum Dis. 2014;73(10):1819–25.
Maksymowych WP. Illness modification in ankylosing spondylitis. Nat Rev Rheumatol. 2010;6(2):75–81.
van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J. Ankylosing Spondylitis Examine for the analysis of recombinant infliximab remedy research, radiographic findings following two years of infliximab remedy in sufferers with ankylosing spondylitis. Arthritis Rheum. 2008;58(10):3063–70.
van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC Jr. Radiographic development of ankylosing spondylitis after as much as two years of remedy with etanercept. Arthritis Rheum. 2008;58(5):1324–31.
van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R. g. canadian research, A.s. group, Evaluation of radiographic development within the spines of sufferers with ankylosing spondylitis handled with adalimumab for as much as 2 years. Arthritis Res Ther. 2009;11(4):R127.
Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting historical past, ideas, and assays. Cell Stem Cell. 2008;2(4):313–9.
Pineault KM, Music JY, Kozloff KM, Lucas D, Wellik DM. Hox11 expressing regional skeletal stem cells are progenitors for osteoblasts, chondrocytes and adipocytes all through life. Nat Commun. 2019;10(1):3168.
Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells characterize the primary supply of bone shaped by grownup bone marrow. Cell Stem Cell. 2014;15(2):154–68.
Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of irritation. Cell Stem Cell. 2013;13(4):392–402.
Zheng G, Xie Z, Wang P, Li J, Li M, Cen S, Tang S, Liu W, Ye G, Li Y, Wang S, Wu X, Su H, Wu Y, Shen H. Enhanced osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis: a research primarily based on a three-dimensional biomimetic atmosphere. Cell Loss of life Dis. 2019;10(5):350.
Xie Z, Wang P, Li Y, Deng W, Zhang X, Su H, Li D, Wu Y, Shen H. Imbalance between bone morphogenetic protein 2 and Noggin induces irregular osteogenic differentiation of mesenchymal stem cells in Ankylosing Spondylitis. Arthritis Rheumatol. 2016;68(2):430–40.
Xie Z, Yu W, Zheng G, Li J, Cen S, Ye G, Li Z, Liu W, Li M, Lin J, Su Z, Che Y, Ye F, Wang P, Wu Y, Shen H. TNF-alpha-mediated m(6)a modification of ELMO1 triggers directional migration of mesenchymal stem cell in ankylosing spondylitis. Nat Commun. 2021;12(1):5373.
Li X, Wang J, Zhan Z, Li S, Zheng Z, Wang T, Zhang Okay, Pan H, Li Z, Zhang N, Liu H. Irritation intensity-dependent expression of Osteoinductive wnt proteins is essential for ectopic new bone formation in Ankylosing Spondylitis. Arthritis Rheumatol. 2018;70(7):1056–70.
Yang Y, Dai M. Expression of PADI4 in sufferers with ankylosing spondylitis and its function in mediating the consequences of TNF-alpha on the proliferation and osteogenic differentiation of human mesenchymal stem cells. Int J Mol Med. 2015;36(2):565–70.
Zubkova ES, Beloglazova IB, Makarevich PI, Boldyreva MA, Sukhareva OY, Shestakova MV, Dergilev KV, Parfyonova YV, Menshikov MY. Regulation of adipose tissue stem cells angiogenic potential by Tumor Necrosis factor-alpha. J Cell Biochem. 2016;117(1):180–96.
Blaser H, Dostert C, Mak TW, Brenner D. TNF and ROS crosstalk in irritation. Developments Cell Biol. 2016;26(4):249–61.
Li L, Lu Y, Xu X, Yang X, Chen L, Jiang C, Wang Y, Hu W, Wei X, Yang Z. Catalytic-enhanced lactoferrin-functionalized Au-Bi(2) Se(3) nanodots for Parkinson’s Illness Remedy through reactive oxygen attenuation and mitochondrial safety. Adv Healthc Mater. 2021;10(13):e2100316.
Yang Y, Guo L, Wang Z, Liu P, Liu X, Ding J, Zhou W. Focused silver nanoparticles for rheumatoid arthritis remedy through macrophage apoptosis and re-polarization. Biomaterials. 2021;264:120390.
Kumar S, Adjei IM, Brown SB, Liseth O, Sharma B. Manganese dioxide nanoparticles shield cartilage from inflammation-induced oxidative stress. Biomaterials. 2019;224:119467.
Kim J, Kim HY, Music SY, Go SH, Sohn HS, Baik S, Soh M, Kim Okay, Kim D, Kim HC, Lee N, Kim BS, Hyeon T. Synergistic oxygen era and reactive oxygen species scavenging by Manganese Ferrite/Ceria co-decorated nanoparticles for rheumatoid arthritis remedy. ACS Nano. 2019;13(3):3206–17.
Das S, Neal CJ, Ortiz J, Seal S. Engineered nanoceria cytoprotection in vivo: mitigation of reactive oxygen species and double-stranded DNA breakage resulting from radiation publicity. Nanoscale. 2018;10(45):21069–75.
Wang D, Goldring SR. The bone, the joints and the balm of Gilead. Mol Pharm. 2011;8(4):991–3.
Zhu G, Chen X. Aptamer-based focused remedy. Adv Drug Deliv Rev. 2018;134:65–78.
Petrocca F, Lieberman J. Promise and problem of RNA interference-based remedy for most cancers. J Clin Oncol. 2011;29(6):747–54.
Apparailly F, Jorgensen C. siRNA-based therapeutic approaches for rheumatic illnesses. Nat Rev Rheumatol. 2013;9(1):56–62.
Czech MP, Aouadi M, Tesz GJ. RNAi-based therapeutic methods for metabolic illness. Nat Rev Endocrinol. 2011;7(8):473–84.
Liang C, Guo B, Wu H, Shao N, Li D, Liu J, Dang L, Wang C, Li H, Li S, Lau WK, Cao Y, Yang Z, Lu C, He X, Au DW, Pan X, Zhang BT, Lu C, Zhang H, Yue Okay, Qian A, Shang P, Xu J, Xiao L, Bian Z, Tan W, Liang Z, He F, Zhang L, Lu A, Zhang G. Aptamer-functionalized lipid nanoparticles focusing on osteoblasts as a novel RNA interference-based bone anabolic technique, Nat Med 21(3) (2015) 288 – 94.
Cao F, Zhang L, Wang H, You Y, Wang Y, Gao N, Ren J, Qu X. Defect-Wealthy Adhesive Nanozymes as environment friendly antibiotics for enhanced bacterial inhibition. Angew Chem Int Ed Engl. 2019;58(45):16236–42.
Knop Okay, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug supply: professionals and cons in addition to potential alternate options. Angew Chem Int Ed Engl. 2010;49(36):6288–308.
Zhao Z, Ukidve A, Kim J, Mitragotri S. Concentrating on methods for tissue-specific drug supply. Cell. 2020;181(1):151–67.
Hess Okay, Ushmorov A, Fiedler J, Brenner RE, Wirth T. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone. 2009;45(2):367–76.
Hayden MS, Ghosh S. Regulation of NF-kappaB by TNF household cytokines. Semin Immunol. 2014;26(3):253–66.
Yu H, Lin L, Zhang Z, Zhang H, Hu H. Concentrating on NF-kappaB pathway for the remedy of illnesses: mechanism and medical research. Sign Transduct Goal Ther. 2020;5(1):209.
Denu RA, Hematti P. Results of Oxidative Stress on Mesenchymal Stem Cell Biology, Oxid Med Cell Longev 2016 (2016) 2989076.
Li Q, Gao Z, Chen Y, Guan MX. The function of mitochondria in osteogenic, adipogenic and chondrogenic differentiation of mesenchymal stem cells. Protein Cell. 2017;8(6):439–45.
Ruutu M, Thomas G, Steck R, Degli-Esposti MA, Zinkernagel MS, Alexander Okay, Velasco J, Strutton G, Tran A, Benham H, Rehaume L, Wilson RJ, Kikly Okay, Davies J, Pettit AR, Brown MA, McGuckin MA. Thomas, beta-glucan triggers spondylarthritis and Crohn’s disease-like ileitis in SKG mice. Arthritis Rheum. 2012;64(7):2211–22.
Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuru S, Sakaguchi S. Altered thymic T-cell choice resulting from a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 2003;426(6965):454–60.
Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Adjustments in bone density in sufferers with ankylosing spondylitis: a two-year follow-up research. Osteoporos Int. 2001;12(7):605–9.
Klingberg E, Lorentzon M, Mellstrom D, Geijer M, Gothlin J, Hilme E, Hedberg M, Carlsten H. Forsblad-d’Elia, osteoporosis in ankylosing spondylitis – prevalence, danger elements and strategies of evaluation. Arthritis Res Ther. 2012;14(3):R108.
van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA. Horst-Bruinsma, Excessive prevalence of low bone mineral density in sufferers inside 10 years of onset of ankylosing spondylitis: a scientific evaluate. Clin Rheumatol. 2012;31(11):1529–35. van der.
Keller KK, Lindgaard LM, Wogensen L, Dagnaes-Hansen F, Thomsen JS, Sakaguchi S, Stengaard-Pedersen Okay, Hauge EM. SKG arthritis as a mannequin for evaluating therapies in rheumatoid arthritis with particular give attention to bone adjustments. Rheumatol Int. 2013;33(5):1127–33.
Shimizu T, Takahata M, Kimura-Suda H, Kameda Y, Endo Okay, Hamano H, Hiratsuka S, Ota M, Sato D, Ito T, Todoh M, Tadano S, Iwasaki N. Autoimmune arthritis deteriorates bone amount and high quality of periarticular bone in a mouse mannequin of rheumatoid arthritis. Osteoporos Int. 2017;28(2):709–18.
Rudwaleit M, van der Heijde D, Landewe R, Itemizing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J. The event of Evaluation of SpondyloArthritis worldwide Society classification standards for axial spondyloarthritis (half II): validation and ultimate choice, Ann Rheum Dis 68(6) (2009) 777 – 83.
Appel H, Kuhne M, Spiekermann S, Kohler D, Zacher J, Stein H, Sieper J, Loddenkemper C. Immunohistochemical evaluation of hip arthritis in ankylosing spondylitis: analysis of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum. 2006;54(6):1805–13.
Klingberg E, Lorentzon M, Gothlin J, Mellstrom D, Geijer M, Ohlsson C, Atkinson EJ, Khosla S, Carlsten H. Forsblad-d’Elia, Bone microarchitecture in ankylosing spondylitis and the affiliation with bone mineral density, fractures, and syndesmophytes. Arthritis Res Ther. 2013;15(6):R179.
Wang CM, Tsai SC, Lin JC, Wu YJ, Wu J, Chen JY. Affiliation of genetic variants of RANK, RANKL, and OPG with Ankylosing Spondylitis Scientific options in taiwanese. Mediators Inflamm. 2019;2019:8029863.
Vernekar AA, Das T, Ghosh S, Mugesh G. A remarkably environment friendly MnFe2 O4 -based Oxidase Nanozyme. Chem Asian J. 2016;11(1):72–6.
Wang P, Li Y, Huang L, Yang J, Yang R, Deng W, Liang B, Dai L, Meng Q, Gao L, Chen X, Shen J, Tang Y, Zhang X, Hou J, Ye J, Chen Okay, Cai Z, Wu Y, Shen H. Results and security of allogenic mesenchymal stem cell intravenous infusion in lively ankylosing spondylitis sufferers who failed NSAIDs: a 20-week medical trial, Cell Transpl 23(10) (2014) 1293 – 303.
Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa Okay, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Make investments. 2004;114(4):582–8.
